Search research articles
Contact Us
Filters
Showing results (31-40 of 111) with videos related to
Page
of 12
Sort By:
International Journal of Molecular Sciences
|
March 29, 2023
Distinct Plasma Immune Profile in ALS Implicates sTNFR-II in pAMPK/Leptin Homeostasis
Vincent Picher-Martel, Hejer Boutej, Alexandre Vézina, et al.
Neuroimage. Clinical
|
September 2, 2020
Involvement of the dentate nucleus in the pathophysiology of amyotrophic lateral sclerosis: A multi-center and multi-modal neuroimaging study
Komal Bharti, Muhammad Khan, Christian Beaulieu, et al.
Brain Communications
|
February 5, 2021
Cerebral atrophy in amyotrophic lateral sclerosis parallels the pathological distribution of TDP43
Mahsa Dadar, Ana Laura Manera, Lorne Zinman, et al.
Neurology
|
July 11, 2020
A prospective harmonized multicenter DTI study of cerebral white matter degeneration in ALS
Sanjay Kalra, Hans-Peter Müller, Abdullah Ishaque, et al.
Muscle & Nerve
|
August 11, 2021
Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollment
Steve Vucic, Toby A Ferguson, Catherine Cummings, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
June 3, 2024
International network for ALS research and care (INARC)
Juliette Foucher, Tommy M Bunte, Vanessa Bertone, et al.
Expert Review of Neurotherapeutics
|
August 30, 2023
Oral Edaravone - Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis
Gary L Pattee, Angela Genge, Philippe Couratier, et al.
JAMA Neurology
|
September 11, 2023
Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial
Angela Genge, Leonard H van den Berg, Glen Frick, et al.
The Lancet. Neurology
|
September 18, 2021
Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial
Merit Cudkowicz, Angela Genge, Nicholas Maragakis, et al.
Journal of Neurology
|
June 12, 2025
Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis
Channa Hewamadduma, Miriam Freimer, Angela Genge, et al.
Page
of 12
Search research articles
Search
Showing results (31-40 of 111) with videos related to
Sort By:
Page
of 12
International Journal of Molecular Sciences
|
March 29, 2023
Distinct Plasma Immune Profile in ALS Implicates sTNFR-II in pAMPK/Leptin Homeostasis
Vincent Picher-Martel, Hejer Boutej, Alexandre Vézina, et al.
Neuroimage. Clinical
|
September 2, 2020
Involvement of the dentate nucleus in the pathophysiology of amyotrophic lateral sclerosis: A multi-center and multi-modal neuroimaging study
Komal Bharti, Muhammad Khan, Christian Beaulieu, et al.
Brain Communications
|
February 5, 2021
Cerebral atrophy in amyotrophic lateral sclerosis parallels the pathological distribution of TDP43
Mahsa Dadar, Ana Laura Manera, Lorne Zinman, et al.
Neurology
|
July 11, 2020
A prospective harmonized multicenter DTI study of cerebral white matter degeneration in ALS
Sanjay Kalra, Hans-Peter Müller, Abdullah Ishaque, et al.
Muscle & Nerve
|
August 11, 2021
Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollment
Steve Vucic, Toby A Ferguson, Catherine Cummings, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
June 3, 2024
International network for ALS research and care (INARC)
Juliette Foucher, Tommy M Bunte, Vanessa Bertone, et al.
Expert Review of Neurotherapeutics
|
August 30, 2023
Oral Edaravone - Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis
Gary L Pattee, Angela Genge, Philippe Couratier, et al.
JAMA Neurology
|
September 11, 2023
Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial
Angela Genge, Leonard H van den Berg, Glen Frick, et al.
The Lancet. Neurology
|
September 18, 2021
Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial
Merit Cudkowicz, Angela Genge, Nicholas Maragakis, et al.
Journal of Neurology
|
June 12, 2025
Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis
Channa Hewamadduma, Miriam Freimer, Angela Genge, et al.
Page
of 12